05 November, 2014 - Wednesday
Marriot Marquis San Diego Marina333 WEST HARBOR DRIVE, SAN DIEGO, CA


5:00 pm Registration Opens

5:30-7 pm Reception

7-8 pm Seminar

8 pm Dinner

Meeting Materials


Chintu Patel, RPh

Designation: CEO & Co-Chairman of Amneal Pharmaceuticals

Chintu Patel, R.Ph., Co-CEO and Co-Chairman of Amneal Pharmaceuticals LLC, has over 20 years of experience in the pharmaceutical industry. With a vision of building an innovative pharmaceutical company based on quality and integrity, he co-founded Amneal in 2002. The firm is currently the 7th largest U.S. generic drug supplier in number of prescriptions dispensed, according to IMS Health, and offers a diversified portfolio of over 80 FDA-approved products. Amneal currently employs 2650 worldwide and operates nine state-of-the-art manufacturing plants in the U.S. and India. Within the next year, the company will be supplying generic pharmaceuticals worldwide. Chintu is passionate about the pursuit of excellence in research, development and quality. He and his brother Chirag Patel, Amneal Co-CEO & Chairman, were honored with the Ernst & Young National Entrepreneur of the Year® 2011 Life Sciences Award for their business achievements. Dedicated to supporting both business and non-profit organizations, Chintu has been a featured speaker at the Hauppauge Industrial Association (NY) and serves on the boards of the Long Island Association and the Make-a-Wish Foundation. He was honored by the Nargis Dutt Memorial Foundation and has been involved with Habitat for Humanity and the educational non-profit KaBoom!. Previously Chintu was a pharmacist and senior-level manager with Eckerd Pharmacy, where he won numerous awards, from 1994 to 2002. He holds a bachelor’s degree in pharmacy from Rutgers College of Pharmacy.


Mr. Chintu Patel through his flagship company Amneal Pharmaceuticals has played an instrumental role in the evolution of the pharmaceutical drug development (small and large molecules) both in new drug application (NDA) and abbreviated new drug application (ANDA), and is viewed as one of the key opinion leaders in the Pharmaceutical Industry. In his talk, he will be focusing on how the traditional research oriented pharmaceutical industry dominated by big pharma has evolved and transitioned into biotech and technology platform driven development stage companies. While new research continues to break through barriers to discover newer disease modifying therapies, the importance of generic and biosimilar drugs continues to grow in importance due to their global reach of patients. Both these segments are moving towards a healthy balance with concepts such as outcome based research and health economics influencing new drugs and market forces such as pricing, healthcare spending and overall cost savings governing generics. At the center of all the innovation are the patients and caregivers who are increasingly seen as most important ‘customer’ to serve.  This has fueled the recent advances in integrative and personalized medicine approaches which is the future of the pharmaceutical space.  

Contact Information

Rina Chokshi